Clinical trial
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
NCT00372697 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00372697 |
|---|---|
| Title | Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly |
| Official title | A Randomised, Open-label, Multicenter Study Comparing the Efficacy and Safety of Medical Treatment With Octreotide Acetate 30 mg Administered Every 21 Days for 6 Months With That of Octreotide Acetate 60 mg Administered Every 28 Days for 6 Months in Acromegalic Patients With Uncontrolled Disease |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Octreotide acetate 30 mg suspension |
| Enrollment | 28 |
| Start date | Dec 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Sep 7, 2006 |
| Last update posted | May 17, 2011 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: